QIAGEN is a Venlo-based Sample-to-Insight tools company whose second quarter confirmed a harder truth than the beat implies. Management had already cut the year after immigration testing and cautious United States life-science budgets emptied the first-quarter outlook. The June print then cleared that lowered bar because five named growth pillars still expanded while the rest of the book contracted. The equity now prices a high-margin consumables franchise that has given back the mid-single-digit growth story it sold at the start of the year. The live question is whether those pillars restore company-level growth in the second half without surrendering the near-thirty-percent adjusted operating margin that is the actual product.
The pillars grew about 5% at constant exchange rates. Sample technologies printed $182 million. That line rose at a 9% constant-currency clip, though only a third of the gain was organic once Parse Biosciences is stripped out. QuantiFERON, the latent-tuberculosis blood test, returned $131 million and grew 1% as core conversion from the skin test offset a large immigration hole. Adjusted operating margin held at 29.4%, a sequential repair from the first quarter and only a modest give-up versus last year. Cash generation stayed intact even after a half-billion synthetic repurchase in January. The counterargument is simple: a beat against a cut outlook is not a re-acceleration.
The next two quarters decide whether the standalone plan still works. Management guides full-year sales growth of about one to two percent at constant exchange rates and adjusted diluted earnings of at least $2.43. That path assumes the second half accelerates after NeuMoDx and Dialunox drop out of the comparison and after new sample-prep systems, bloodstream-infection panels, and Parse contribute. Jonathan Pratt took over as chief executive on the first of September while the Supervisory Board keeps a strategic review open with outside advisors. Does the second half deliver the mid-single-digit constant-currency growth the year requires, or does the review become the real event because the organic story has already been marked down?